(AOF) – The consolidated turnover of the PCAS Group increased by 3.3% in the first half to 109.80 million euros. It increased by 1.4% at constant exchange rates. The chemical group has warned that over this period, current operating income will remain very negative, affected by a level of activity still insufficient to cover fixed costs on several sites in Pharmaceutical Synthesis, as well as by inventory write-downs relating to products non-compliant.
In addition, the 2022 half-year financial statements will include a charge of €14.5 million corresponding to an impairment of the group’s goodwill, the immediate consequence of an increase in the discount rate used to determine operating cash flows. futures as part of the impairment tests.
PCAS stresses that it is fully mobilized “for an improvement in results in 2022 and a return to positive results in 2023, helped in this by a gradual growth in Estetrol volumes for Mithra”.
AOF – LEARN MORE